Microbiota–sphingolipid pathway in generalized epilepsy: evidence from Mendelian randomization and clinical metabolomics
This study identifies both unidirectional and bidirectional microbiota-metabolite pathways modulating generalized epilepsy risk, with converging evidence pointing to sphingomyelin as a potential lipid biomarker and therapeutic target.
Authors
- Huapin Huang (ORCID: https://orcid.org/0000-0003-0476-756X)
- Shenggen Chen
- Chaofeng Zhu
- Ming-xing Lin
- Lizhen Chen (ORCID: https://orcid.org/0000-0001-5313-7340)
- Yuying Zhang (ORCID: https://orcid.org/0000-0002-6070-7011)
- Wenting Xiong
- Wanhui Lin (ORCID: https://orcid.org/0000-0002-9100-0449)
- Jiayin Gong
- Changyun Liu (ORCID: https://orcid.org/0009-0006-8030-8911)
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Microbiology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fmicb.2025.1662050
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Fujian Medical University